Chief Medical Officer · Avalo Therapeutics, Inc. (AVTX)

Mittle Doyle

FY2024 is the first fiscal year CompBrief holds for Mittle Doyle as a named executive officer of Avalo Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,033,757

Salary $231,061Stock awards $0

2nd of 4 named executive officers at Avalo Therapeutics by FY2024 total.

4 named officers on file for Avalo Therapeutics, FY2024

Mittle Doyle’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Avalo Therapeutics’s whole pay program stands against its peers

  • Avalo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2025 (DEF 14A).

Free

Get Mittle Doyle’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mittle Doyle compensation by year

Avalo Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Avalo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$231,061
Bonus$0
Stock awards$0
Option awards$2,586,696
Non-equity incentive$216,000
Pension and deferred compensation$0
All other$0
Total$3,033,757

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed May 1, 2025, accession 0001628280-25-021311, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001628280-25-021311. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option234,000—$12.65

Per the Outstanding Equity Awards at Fiscal Year-End table in Avalo Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Avalo Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Garry NeilChief Executive Officer, President and principal executive officer$7,212,749
Mittle Doyle · this pageChief Medical Officer$3,033,757
Mittie FACRChief Medical Officer$3,033,757
Christopher SullivanChief Financial Officer and principal financial officer$2,929,534

The full Avalo Therapeutics compensation record

free company brief

This page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mittle Doyle's compensation dossier · One-time report. No refunds.